4-methoxy-3-phenoxybenzoic acid | 63987-21-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-methoxy-3-phenoxybenzoic acid
• 英文别名: 4-methoxy-3-phenoxy-benzoic acid；4-Methoxy-3-phenoxy-benzoesaeure；3-phenoxy-4-methoxybenzoic acid
• CAS: 63987-21-3
• 化学式: C₁₄H₁₂O₄
• 分子量: 244.247
• InChiKey: GJEJAYZOIQJPLJ-UHFFFAOYSA-N

物化性质

• 熔点：
  187-187.5 °C
• 沸点：
  389.6±27.0 °C(Predicted)
• 密度：
  1.242±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-methoxy-3-phenoxybenzoic acid 在 三氯化铝 、 苯 作用下， 生成 4-hydroxy-3-phenoxy-benzoic acid
  参考文献：
  名称：

  The Gattermann Reaction in the Mono-methoxydiphenyl Ethers¹

  摘要：

  DOI：

  10.1021/ja01249a024
• 作为产物：
  描述：

  3-羟基-4-甲氧基苯甲酸甲酯 在 copper diacetate 、 三乙胺 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 85.0h， 生成 4-methoxy-3-phenoxybenzoic acid
  参考文献：
  名称：

  Novel Class of Benzoic Acid Ester Derivatives as Potent PDE4 Inhibitors for Inhaled Administration in the Treatment of Respiratory Diseases

  摘要：

  The first steps in the selection process of a new anti-inflammatory drug for the inhaled treatment of asthma and chronic obstructive pulmonary disease are herein described. A series of novel ester derivatives of 1-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3,5-di-chloropyriclin-4-yl) ethanol have been synthesized and evaluated for inhibitory activity toward cAMP-specific phosphodiesterase-4 (PDE4). In particular, esters of variously substituted benzoic acids were extensively explored, and structural modification of the alcoholic and benzoic moieties were performed to maximize the inhibitory potency. Several compounds with high activity in cell-free and cell-based assays were obtained. Through the evaluation of opportune in vitro ADME properties, a potential candidate suitable for inhaled administration in respiratory diseases was identified and tested in an in vivo model of pulmonary inflammation, proving its efficacy.

  DOI：

  10.1021/jm401549m

文献信息

• Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
  申请人：Warner-Lambert Company

  公开号：US06268387B1

  公开（公告）日：2001-07-31

  The present invention provides compounds of formula (I). The present invention also provides methods of treating or preventing inflammation or atherosclerosis, and a pharmaceutical composition that contains a compound of formula (I).

  本发明提供了化合物的结构式（I）。本发明还提供了治疗或预防炎症或动脉粥样硬化的方法，以及含有结构式（I）化合物的药物组合物。
• Liquid crystalline copolyesters of 4-hydroxybenzoic acid and substituted
  申请人：The Dow Chemical Company

  公开号：US05268443A1

  公开（公告）日：1993-12-07

  The invention relates to a class of copolymers capable of forming an optically anisotropic melt comprising recurring structural units (a) independently each occurrence selected from the group consisting of Formula I; recurring structural units (b) independently each occurrence selected from the group consisting of Formulas II and III; and optionally recurring structural units (c) independently each occurrence selected from the group consisting of Formula IV: ##STR1## wherein R independently each occurrence is a chemically inert substituent.

  本发明涉及一类共聚物，能够形成具有光学各向异性熔体，包括重复结构单元（a），每次独立选择自公式I组成的群体中的一种；重复结构单元（b），每次独立选择自公式II和III组成的群体中的一种；以及可选的重复结构单元（c），每次独立选择自公式IV组成的群体中的一种：##STR1## 其中R每次独立是一种化学惰性取代基。
• Melt processable thermotropic aromatic copolyesters and process for preparing same
  申请人：THE DOW CHEMICAL COMPANY

  公开号：EP0447602A2

  公开（公告）日：1991-09-25

  Disclosed is a copolymer capable of forming an optically anisotropic melt comprising recurring structural units of Formulas I, II, and optionally III wherein each R is independently a chemically inert substituent; and each R¹ is independently benzoil or phenoxy. The present invention also relates to a process for preparing the copolymer. The copolymer of the present invention usually have a melting point below 350°C and can be readily melt extruded into fibers, films or the like.

  本发明公开了一种可形成光学各向异性熔体的共聚物，该共聚物由式 I、II 和可选的 III 的重复结构单元组成 其中每个 R 独立地为化学惰性取代基；每个 R¹ 独立地为苯氧基或苯氧基。本发明还涉及一种制备共聚物的工艺。本发明的共聚物的熔点通常低于 350℃，可以很容易地熔融挤压成纤维、薄膜或类似物。
• Aiding chronic written language expression difficulties: A case study
  作者：Linda Armstrong、Alison Macdonald

  DOI：10.1080/026870300401612

  日期：2000.1

  This paper describes some progress made in helping a young aphasic man (MD) to overcome what had appeared to be intractable written language expression difficulties, which continued to be significant for him. Traditional therapy methods based on cognitive neuropsychological assessment had failed to help MD to generalize improvement in his spelling particularly, but not exclusively, of longer and irregular words. Both a splint which allowed him to use his dominant hand for writing directly onto a computer screen and a simple word-processing programme with synthesized auditory feedback and lexical and grammatical prediction (Write:OutLoud(R) and Co:Writer(R)) enabled him to produce more normal written output (increased quantity and more normal quality). The discussion also focuses on how effectiveness of language therapy can be measured in this man with chronic aphasia.
• Discovery of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid diamides that increase CFTR mediated chloride transport
  作者：Bradford H. Hirth、Shuang Qiao、Lisa M. Cuff、Brian M. Cochran、Marko J. Pregel、Jill S. Gregory、Scott F. Sneddon、John L. Kane

  DOI：10.1016/j.bmcl.2005.02.041

  日期：2005.4

  A series of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid diamides that increase chloride transport in cells expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR) protein has been identified from our compound library. Analoging efforts and the resulting structure-activity relationships uncovered are detailed. Compound potency was improved over 30-fold from the original lead, yielding several analogs with EC50 values below 10 nM in our cellular chloride transport assay. (c) 2005 Elsevier Ltd. All rights reserved.